Dr. Alice Gottlieb is an internationally recognized expert and leader in the field of psoriasis, psoriatic arthritis and related disorders. She is currently Professor of Dermatology at New York Medical College. From 2006 to 2016, Dr. Gottlieb was Chair of Dermatology and Dermatologist-in-Chief at the Tufts Medical Center and Tufts University School of Medicine. She is the former Professor of Medicine and Founding Director of the Psoriasis Center of Excellence at University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School. Dr. Gottlieb is triple-boarded in dermatology, rheumatology and internal medicine, one of only a handful of doctors in the U.S. certified in all three specialties. She obtained her M.D. from Cornell Medical School and her Ph.D. in immunology from the Rockefeller University.
Dr. Gottlieb was elected to the Board of Directors of the American Academy of Dermatology from 2011-2015 and is the Founder and President of the Board of the International Dermatology Outcome Measures group. She is also active as a councilor of the International Psoriasis Council, member of the Executive and Steering Committees of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis, the National Psoriasis Foundation Medical Board, and co-Editor-in-Chief of the Journal of Psoriasis and Psoriatic Arthritis.
Her research has provided new understanding of the pathogenesis of psoriasis and provided the foundation for biologic drug development in psoriasis and psoriatic arthritis. She has authored over 300 publications and presented her research at more than 200 conferences across the globe. She has also presented for NPF patient and provider education events. Dr. Gottlieb has received numerous awards for mentoring and teaching, including the 2016 National Psoriasis Foundation’s Outstanding Educator in Psoriatic Disease Award.
Strober B, Sigurgeirsson Bd, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient reported psoriasis symptoms than placebo and etanercept. JPPA 1: 167-73, 2016.
Kimball AB, Luger T, Gottlieb A, Puig L, Kaufmann R, Nikaï E, Zhu B, Edson-Heredia E, Carlier H, Lin CY, Goldblum O, Yosipovitch G. Impact of ixekizumab on psoriasis itch severity and other psoriasis symptoms: Results from 3 phase III psoriasis clinical trials.J Am Acad Dermatol. 2016 Sep 27. pii: S0190-9622(16)30563-1. doi: 10.1016/j.jaad.2016.07.034. [Epub ahead of print] .JAAD 2016;75:1156-61
Gottlieb Alice, Menter Alan, Armstrong April, Ocampo Christopher, Gu Yihua, Teixeira Henrique D: Adalimumab treatment in women with moderate-to-severe hidradenitis suppurativa from the placebo-controlled portion of a phase 2, randomized, double-blind study. J. Drugs Dermatol.15: 1192-1196, 2016.
Gottlieb AB, Blauvelt A, Prinz JC, Papanastasiou P, Pathan R, Nyirady J, Fox T, Papavassilis C: Secukinumab self-administration by prefilled syringe maintains reduction of plaque psoriasis severity over 52 weeks: Results of the FEATURE trial. J Drugs Dermatol. 15: 1226-1234, 2016.
Kurayev A and Gottlieb AB: Candida esophagitis associated with mycophenolate mofetil treatment of atopic dermatitis. J Drugs Dermatol 15: 1267-1269, 2016.
Kristina Duffin MD MS,a Kim A. Papp MD PhD,b Jerry Bagel MD,c Eugenia Levi PharmD BCPS,d Rongdean Chen PhD,d and Alice B. Gottlieb MD PhD. Evaluation of the Physician Global Assessment and Body Surface Area Composite Tool for Assessing Psoriasis Response to Apremilast Therapy: Results From ESTEEM 1 and ESTEEM 2, J. Drugs. Dermatol. 16;147-53, 2017.
Strober B, Gottlieb AB, Sherif B, Mollon P, Giloteau I, McLeod L, Fox T, Mordin M, Gnansakthy A, Papvasssilis C Lewbwohl MG: Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from two phase 3 randomized placebo-controlled clinical trials comparing secukinumab with etanecercept, JAAD 76:655-669,2017.
Mease PJ, Gottlieb AB, Berman, Drescher E, Xing J, Wong R, Banerjee S: The efficacy and safety of Clazakizumab, an anti-Interleukin-6 monocolonal antibody, in a Phase IIb study of adults with active psoriatic arthritis. Arthritis and Rheumatology 68: 2163-73, 2016.
Van de Kerkhof, Guenther L, Gottlieb AB, Sebastian M, Wu JJ, Foley P, Morita A, Goldblum O, Zhang L, Erickson J, Ball S, Rich P: Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVEDRF-3., JEADV, in press.
April W. Armstrong, MD, MPH,a Michael P. Siegel, PhD,b Jerry Bagel, MD,c,d Erin E. Boh, MD, PhD,e Megan Buell,b Kevin D. Cooper, MD,f Kristina Callis Duffin, MD, MS,g Lawrence F. Eichenfield, MD,h Amit Garg, MD,i Joel M. Gelfand, MD, MSCE,j Alice B. Gottlieb, MD, PhD,k John Y. M. Koo, MD,l Neil J. Korman, MD, PhD,f Gerald G. Krueger, MD,g Mark G. Lebwohl, MD,m Craig L. Leonardi, MD,n Arthur M. Mandelin, MD, PhD,o M. Alan Menter, MD,p Joseph F. Merola, MD, MMSC,q David M. Pariser, MD,r,s Ronald B. Prussick, MD, FRCP,t Caitriona Ryan, MD,p Kara N. Shah, MD,u Jeffrey M. Weinberg, MD,m MaryJane O. U. Williams, MD,a Jashin J. Wu, MD,v Paul S. Yamauchi, MD, PhD,w and Abby S. Van Voorhees, MDr From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis. ( J Am Acad Dermatol http://dx.doi.org/10.1016/j.jaad.2016.10.017.)
Rahman P, Puig L, Gottlieb AB, Kavanaugh A, McInnes IB, Ritchlin C, Li S, Wang Y, Song M, Mendelsohn A, Han C on behalf of the Summit 1 and 2 Study groups. Ustekinumab Treatment and Improvement of Physical Function and Health-Related Quality of Life in Patients With Psoriatic Arthritis Care & Research Vol. 68, No. 12, December 2016, pp 1812–1822
Thoriacius L, Ingram JR, Garg A, Vilumsen B, Esmann S, Kirby JS, Gottlieb AB, Merola, JF, Dellavalle R, Christensen R, Jemec GBE. Protocol of the development of a core domain set for hidradenitis suppurativa trial outcomes, BMJ Open, in press.
Rothstein B, Joshipura D, Saraiya A, Abdat H, Turkowski Y, Sheth V, Huang V, Au SC, Kachuk C, Dumont N, Gottlieb AB, Rosmarin D. Treatment of Vitiligo with Topical Janus Kinase Inhibitor Ruxolitinib, JAAD, ( J Am Acad Dermatol http://dx.doi.org/10.1016/j.jaad.2017.02.049
Egeberg A, Kristensen LE, THyssen JP, Gislason GH, Gottlieb AB, Coates LC, Julien D, Gisondi P, Gladman DD, Skov L, Mallbris. Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. Annals Rheum. Dis., in press.
Elman SA, Merola JF, Armstrong AW, Callis Duffin K, Latealla J, Garg A, Gottlieb AB: The International Dermatology Outcome Measures (IDEOM) Initiative: A Review and Update. J.Drugs Dermatol. 16:119-124, 2017.
Gottlieb AB, Strober B, Lebwohl M, Kaurmann R, Pariser D, Narbutas R, Nyirady J, Xhao Y, Herrera V, McLeod L, Odom D, Elewski BE: Greater efficacy with secukinumab treatment is associated with greater psoriasis symptom relief: results from secukinumab clinical trial data. JPPA 2:73-80, 2017.
Bissonnette R, Kerdel F, Naldi L, Papp K, Galindo C, Langholff W, Tang KL, Szapary P, Fakharzadeh S, Srivastava B, Goyal K, Gottlieb AB: Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis. J. Drugs. Dermatol., 16:1002-1013, 2017.
Perez-Chada LM, Singh S, Callis-Duffin K, Garg A, Gottlieb AB, Latella J, Armstrong AW., Merola JF. International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group. J. Drugs Dermatol, in press.
Mease PJ, Gottlieb AB, Van der Heijde, Fitzgerald O, Johnsen A, Nys M, Banerjee S, Gladman, DD. Efficacy and safety of abatacept, a T-cell modulator, in a randomized, double-blind, placebo-controlled, phase III study in psoriatic arthritis. ARD Online First, published on May 4, 2017 as 10.1136/annrheumdis-2016-210724.
Joshipura D, Plotnikova N, Goldminz A, Deverapalli S, Turkowski Y, Gottlieb AB, Rosmarin D. Importance of Light in the Treatment of Vitiligo with JAK-inhibitors. J. Dermatol. Treatment. DOI: 10.1090/09546634.2017.1339013, 2017.
Joshipura D, Goldminz A Greb J, Gottlieb A: Acitretin for the treatment of recalcitrant plantar warts. Dermatol Online J. 2017 Mar 15: 23 (3), Pii: 13030lqt721426pm
Abdat R, Lim YJ, Joshipura D, Goldminz A, Gottlieb AB: Patient-reported outcomes measures in psoriasis. JPPA 2:41-46.
Osier E, Wang AS, Tellefson MM , Cordora KM, Daniels SR, Eichenfield A, Gelfand JM, Gottlieb AB, Kimball AR, Lebwohl M, Mehta NN, Paller AS, Schwimmer JB, Styne DM, Voorhees AS van, Tom WL, Eichenfield LF. Pediatric psoriasis comorbidity screening guidelines. JAMA Derm 153: 698-704, 2017.
Merola JF, Bleakman AP, Gottlieb AB, Menter A, Naegeli AN, BIssonnette R, Guenther L, Sullivan J, Meeuwis K, See K, Callis Duffin K. The static physician physician’s global assessment of genitalia: a clinical outcome measure for the severity of genital psoriasis. J. Drugs Dermatol 16: 793-799.
Perez-Chada LM, Singh S, Callis-Duffin K, Garg A, Gottlieb AB, Latella J, Armstrong AW, Merola JF. International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group. J. Drugs. Dermatol. 2017; 16: 770-777.
Merola JF, Bleakman AP, Gottlieb AB, Menter A, Naegeli AN, Bissonnette R, Guenther L, Sullivan J, Meeuwis K, See K, Callis-Duffin K: The static physician’s global assessment of genitalia: A clinical outcome measure for the severity of genital psoriasis. J. Drugs. Dermatol. 2017 16: 793-799.
McInnes IB, Mease PJ, Ritchlin CT, Rahman P, Gottlieb AB, Kirkham B, Kejakar R, Delicha EpM, Pricop L, Mpofu S: Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study. J. Rheumatology doi: 10.1093/rheumatology/kex301, 2017.
Bissonnette R, Kerdel F, Naldi L, Papp K, Galindo C, Langholff W, Tang KL, Szapary P, Fakharzadeh S, Srivastava B, Goyal K, Gottlieb AB: Evaluation of risk of major adverse cardiovascular events with biologic therapy in patients with psoriasis. J.Drugs. Dermatol. 16:1002-13, 2017.
Coates LC, Fitzgerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Duffin KC, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Krestensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen C, Strand V, Tillett W, Veale DJ, Helliwell PS. GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PSA, Arthritis and Rheumatology, in press.
L. Thorlacius, A. Garg, J.R. Ingram, B. Villumsen, P. Theut Riis, Alice B. Gottlieb, Joseph F. Mola, Robert Dellavalle, C. Ardon, R. Baba, F.G. Bechara, A.D. Cohen, N. Daham, M. Davis, L. Emtestam, P. FernandezPenas,. Filippelli, A. Gibbons, T. Grant, S. Guilbault, S. Gulliver, C Harris, C. Harvent, K. Houston, J. S. Kirby, L. Matusiak, A. Mehdizadeh, T. Mojica, M. Okun, D. Orgill, L. Pallack, A. Parks-Miller, E.P. Prens, S. Randell, C. Rogers, C.F. Rosen, S.E. Choon, H.H. van der Zee,, R. Christensen, G.B.E. Jemec. Towards global consensus on core outcomes for hidradenitis suppurativa research: An update from the HISTORIC consensus meetings I and II, Br. J. Dermatol. , in press.
Gottlieb AB, Merola JF, Chen r, Levi E, Callis Duffin K: Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA x BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data. JAAD 77: 1178-1180, 2017.
Gottlieb AB, Kirby B, Ryan C,Naegeli AN, Burge R, Bleakman AP, Anatchkova MD, Yosipovitch G. The development of a patient-reported measure for assessment of genital psoriasis symptoms: The genital psoriasis symptoms scales (GPSS). Dermatology and Therapy published online. https://doi.org/10.1007/s135555-017-0213-2, 2017
Gottlieb AB, Kirby B, Ryan C, Naegeli AN, Burge R, Bleakman AP, Anatchkova MD, Cather J: The development of the genital psoriasis sexual frequency questionnaire (GenPs-SFQ) to assess the impact of genital psoriasis on sexual health. Dermatology and Therapy, published online. https://doi.org/10.1007/s13555-017-0212-3, 2017